This drug regimen is intended and approved for adults with HIV-1 infection who have had no previous antiretroviral treatment or for those with less than 50 copies of HIV-1 RNA per mL. Patients with HIV-1 should not have previously had any adverse reactions or resistance to<unk> , emtricitabine, or tenofovir<unk> .
Bictegravir/emtricitabine/tenofovir alafenamide
Doravirine/lamivudine/tenofovir
Dolutegravir/lamivudine/tenofovir
Lamivudine/tenofovir
Atazanavir/ritonavir
Abacavir/lamivudine/zidovudine
Emtricitabine/rilpivirine/tenofovir
Abacavir/lamivudine